These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 826840)

  • 1. [Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome].
    Binder H; Gerstenbrand F; Grünberger J; Gründig E; Schubert H
    Nervenarzt; 1976 Nov; 47(11):656-60. PubMed ID: 826840
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical aspects and pathogenesis of the "on-off" phenomenon in Parkinson syndrome].
    Jörg J; Schneider I
    Fortschr Neurol Psychiatr; 1988 Jan; 56(1):22-34. PubMed ID: 3126121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term levodopa syndrome. Report of a clinical case].
    Bossi L; Nobili M
    Arch Sci Med (Torino); 1978; 135(4):637-9. PubMed ID: 756726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary assessment of the effectiveness of L-dopa with prolonged action (Medidopa retard) as compared to conventional L-dopa preparation].
    Friedman A
    Neurol Neurochir Pol; 1978; 12(1):39-43. PubMed ID: 634431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa].
    Gisselmann A; Boudry C; Marin A; Ballivet J
    Encephale; 1976; 2(2):105-13. PubMed ID: 1278088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Nervenarzt; 1977 Apr; 48(4):205-10. PubMed ID: 404579
    [No Abstract]   [Full Text] [Related]  

  • 8. [Medical management and social status of elderly Parkinson patients].
    Vieregge P; Körtke D; Meyer-Bornsen C
    Z Gerontol; 1994; 27(4):260-9. PubMed ID: 7975817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Review of problems in the treatment of the parkinsonian syndrome with L-dopa].
    Piccirilli M; Quartesan R
    Clin Ter; 1976 Mar; 76(5):467-77. PubMed ID: 991553
    [No Abstract]   [Full Text] [Related]  

  • 10. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P; Ziegler M; Aymard N; Holzer J
    Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 13. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
    Chouza C; Romero S; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations.
    Chase TN; Juncos J; Serrati C; Fabbrini G; Bruno G
    Adv Neurol; 1987; 45():477-80. PubMed ID: 3103391
    [No Abstract]   [Full Text] [Related]  

  • 15. Observations made with L-deprenil (Jumex) in the long-term treatment of outpatients with Parkinson's syndrome.
    Gyimóti G; Csanaky A; Leposa D
    Ther Hung; 1983; 31(1):26-30. PubMed ID: 6443750
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.
    Chouinard G; Annable L; Mercier P; Turnier L
    Psychopharmacol Bull; 1987; 23(1):221-6. PubMed ID: 2885889
    [No Abstract]   [Full Text] [Related]  

  • 17. [The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
    Sommer H; Fischer GJ; Quandt J
    Folia Clin Int (Barc); 1974 Oct; 24(10):681-95. PubMed ID: 4279185
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical effect of L-dopa on schizophrenia.
    Ogura C; Kishimoto A; Nakao T
    Curr Ther Res Clin Exp; 1976 Sep; 20(3):308-18. PubMed ID: 9266
    [No Abstract]   [Full Text] [Related]  

  • 19. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of biperiden in delayed-release form in the treatment of Parkinson's disease and parkinsonian syndromes of various etiologies. Clinical experiments].
    Puntoni U
    Clin Ter; 1983 Oct; 107(1):37-44. PubMed ID: 6653070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.